Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516).
Dory Abelman, PhD(c), HBHSc, of the University of Toronto, discusses findings that support the feasibility of ultradeep cell-free DNA whole-genome sequencing for comprehensive genomic profiling in patients with multiple myeloma, which may be a less invasive alternative to bone marrow biopsy (Abstract 495).
Amer Zeidan, MBBS, of Yale School of Medicine, shares results from the phase I/II BEXMAB study, which examined the safety, tolerability and preliminary efficacy of bexmarilimab—a novel macrophage checkpoint inhibitor targeting Clever-1—in combination with the standard of care, azacitidine, in patients with higher-risk myelodysplastic syndromes (MDS), including those with TP53-mutated disease. (Abstract 236).
Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe cases of myelodysplastic syndromes (MDS). Researchers concluded that exposure is associated with younger age at MDS diagnosis, ultimate MDS diagnosis, genetic complexity of MDS, increased risk of disease progression, and with Black race (Abstract 5626).
Andrew Portuguese, MD, of Fred Hutchinson Cancer Center, discusses findings from a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium looking at the real-world safety and efficacy of the BCMA-CD3 bispecific antibody elranatamab (Abstract 136).
Benjamin Diamond, MD, of the University of Miami, describes findings from the single-center phase II REKINDLE trial, which looked at the combination regimen of iberdomide, carfilzomib, daratumumab, and dexamethasone in patients with early relapsed/refractory multiple myeloma (Abstract 251).
